PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.23%
EBIT growth above 1.5x RVPH's 5.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
45.56%
Operating income growth above 1.5x RVPH's 7.11%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
30.89%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
30.77%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
30.77%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.49%
OCF growth above 1.5x RVPH's 38.83%. David Dodd would confirm a clear edge in underlying cash generation.
98.49%
FCF growth above 1.5x RVPH's 38.83%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
94.54%
OCF/share CAGR of 94.54% while RVPH is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
94.54%
5Y OCF/share CAGR above 1.5x RVPH's 21.52%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
94.54%
3Y OCF/share CAGR above 1.5x RVPH's 53.59%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-8.80%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-8.80%
Negative 5Y net income/share CAGR while RVPH is 60.51%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-8.80%
Negative 3Y CAGR while RVPH is 58.01%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-273.39%
Negative equity/share CAGR over 10 years while RVPH stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-273.39%
Negative 5Y equity/share growth while RVPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-273.39%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.09%
Negative asset growth while RVPH invests at 64.40%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.63%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.22%
We have some new debt while RVPH reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-43.90%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.